Hydrocerussite is a basic lead carbonate mineral with the chemical formula Pb3(CO3)2(OH)2. It occurs as colorless to white, yellowish, or greenish, translucent, platy crystals, often in aggregates. Hydrocerussite is a secondary mineral, meaning it forms from the alteration of other lead minerals. It is found in lead ore deposits and is often associated with cerussite (PbCO3) and anglesite (PbSO4).
Hydrocerussite is of interest to researchers for several reasons. First, it is a valuable source of lead. Second, its formation and stability are important in understanding the geochemical processes that govern lead migration in the environment. Third, it is a potential indicator mineral for lead pollution.
Hydrocerussite is known to be toxic, so proper handling and disposal are necessary. It is considered a hazardous waste and should be handled according to local regulations.
Hydrocerussite can be synthesized in the laboratory by reacting lead nitrate with sodium carbonate in an aqueous solution. This reaction is used to study the formation of hydrocerussite and its properties.
Hydrocerussite is a relatively rare mineral, but it is found in several parts of the world, including the United States, Europe, and Australia. It is also found in meteorites and on the Moon.'
hydrocerussite: a minor lead ore [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 14834 |
| MeSH ID | M0524692 |
| Synonym |
|---|
| berlin white |
| einecs 215-290-6 |
| unii-wdf96425hv |
| hsdb 5701 |
| ceruse |
| silver white |
| cerussa |
| carbonic acid, lead salt, basic |
| wdf96425hv , |
| flake lead |
| lead carbonate hydroxide (pb3(co3)2(oh)2) |
| white lead |
| nsc 112221 |
| lead, bis(carbonato(2-))dihydroxytri- |
| lead carbonate hydroxide (pb3(oh)2(co3)2) |
| lead subcarbonate |
| lead, bis(carbonato)dihydroxytri- |
| white lead, hydrocerussite |
| basic lead carbonate (2pbco3.pb(oh)2) |
| ec 215-290-6 |
| basic lead carbonate |
| 1319-46-6 |
| trilead bis(carbonate) dihydroxide |
| lead, bis[carbonato(2-)]dihydroxytri- |
| lead hydroxide carbonate |
| lead(ii) carbonate basic |
| 1319-47-7 |
| hydrocerussite |
| c.i. 77597 |
| basic lead carbonate [mi] |
| lead hydroxide carbonate [hsdb] |
| DTXSID9029641 |
| 1344-36-1 |
| Q656004 |
| lead carbonate basic reagent (acs) |
| lead(2+);dicarbonate;dihydroxide |
| Excerpt | Reference | Relevance |
|---|---|---|
| " It is concluded that standard sequential extraction procedures are probably not very useful in predicting lability and bioavailability of Pb in contaminated soils." | ( Evaluating specificity of sequential extraction for chemical forms of lead in artificially-contaminated and field-contaminated soils. Li, Z; McBride, MB; Tai, Y, 2013) | 0.39 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Under the same experimental conditions, orthophosphate dosing inhibited the formation of Pb(IV) oxides." | ( The inhibition of Pb(IV) oxide formation in chlorinated water by orthophosphate. Lytle, DA; Scheckel, K; Schock, MR, 2009) | 0.35 |
| "Phosphate dosing is the principle strategy used in the United Kingdom to reduce the concentration of lead in tap waters supplied by lead water pipes." | ( Spherulitic Lead Calcium Apatite Minerals in Lead Water Pipes Exposed to Phosphate-Dosed Tap Water. Andrews, H; Banks, J; Casey, H; Coleman, S; Cussons, M; Haley, J; Hopwood, JD; Humphreys, PN; Knott, P, 2023) | 0.91 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (30.53) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||